Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Monday, February 8, 2016 at 1:00 PM ET at the 2016 BIO CEO & Investor Conference.
A live audio webcast of Mr. Gonzalez’s presentation can be accessed at the following URL: http://www.veracast.com/webcasts/bio/ceoinvestor2016/93109214189.cfm. An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors' section of the Navidea website at www.navidea.com.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Tom Baker, 617-532-0624
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications
David Schull or Chris Hippolyte, 858-717-2310